The Swiss pharmaceutical firm Roche has received an emergency authorization from the US Food and Drug Administration (US FDA) for LightMix Ebola Zaire test for emergency use on patients with signs and symptoms of the deadly virus.
Mobile laboratories in Guinea, Sierra Leone and Liberia currently use expensive and time-consuming tests that can take up to six hours. However, the new test can take as little as three hours.
Ebola Virus Disease
Ebola is caused by a virus via direct contact with body fluids or infected blood. Scientists have identified five types of Ebola or Ebola hemorrhagic fever virus.
Advertisement
The Ebola test, manufactured by German company TIB MOLBIOL GmbH, has also been given the European CE mark indicating it abides with the EU regulations.
Chief operations officer of Roche's diagnostics division, Roland Diggelmann said, "The LightMix Ebola Zaire test is an easy-to-use molecular diagnostic test providing a solution for healthcare professionals to quickly detect the virus and start patient treatment as early as possible."
Source: Medindia
Source: Medindia
WHO Meets Targets to Reduce Ebola Spread
The World Health Organization (WHO) has reported of having achieved the targets to reduce the spread of Ebola by isolating patients and burying bodies safely.
Advertisement
 5-day Lockdown in Sierra LeoneTo step up efforts to contain the Ebola epidemic the Sierra Leone government has declared a 5-day lockdown in the country's Northern Province. | Advertisement
|
Nurses Treating Ebola Patients on Strike in Sierra Leone
Due to non-payment of risk allowance by the government for the month of November for treating Ebola patients, about 30 nurses were on strike.
Advertisement
Recommended Readings
Latest Drug News
The psychedelic market set for remarkable growth, projected to hit $7.2B by 2029 with a strong 55% CAGR.
The study explores whether CDNF could influence the progression of ALS in rodent models and to elucidate the mechanism through which it operates.
Amoxicillin-clavulanate use in acute sinusitis patients is associated with a higher incidence of adverse events.
Professionals advocate for enhanced education of patients and caregivers, and creation of more effective child-resistant systems for monitoring ADHD medication.
In June, WHO raised concerns about 7 Indian cough syrups after complaints from several countries about contamination and health issues.
